BTIG analyst Andrew Harte lowered the firm’s price target on Lightspeed (LSPD) to $17 from $21 and keeps a Buy rating on the shares. The shares ...

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Zimmer Biomet Holdings (ZBH – Research Report), with a price ...

BTIG analyst Justin Zelin downgraded Kura Oncology stock (NASDAQ:KURA) from Buy to Neutral. Zelin cited concerns over the recent KOMET-001 study results for the company's drug, ziftomenib. The ...

BTIG analyst Gregory Lewis (JO:LEWJ) revised the price target for Blue Bird Corp (NASDAQ:BLBD) shares to $45.00, down from the previous target of $55.00, while reaffirming a Buy rating on the stock.

While value offerings are helping improve sales, some franchisees have yet to fully recover their visits and sales comps as ...

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced its ...

InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will host investor meetings at the BTIG MedTech, ...

BTIG is a leading global financial services firm specializing in investment banking, institutional trading, research, and ...

Treace provides technology that facilitates Lapiplasty bunion surgery and related midfoot deformities. The company recently ...